Aripiprazole for schizophrenia

El-Sayeh, HG; Morganti, C

doi:10.1002/14651858.cd004578

Cited by 33 publications

(42 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To conduct these systematic reviews, common outcome measures must be collected and reported. One summary in the Cochrane Library states that, “ Despite the fact that 7110 people participated in fifteen randomised aripiprazole studies, we were unable to extract any usable data on death, service outcomes, general functioning, behaviour, engagement with services, satisfaction with treatment; economic outcomes or cognitive functioning.” [9] This statement illustrates the outlined problems of present day studies, their designs and outcome measures used. A few key outcome measures could provide that needed information, at least during the short-duration of most medication trials.…”

Section: Importance Of Systematic Reviewsmentioning

confidence: 99%

Another Look at Outcomes and Outcome Measures in Psychiatry: Cui bono?

Arfken

Balon²

2013

Psychother Psychosom

View full text Add to dashboard Cite

Section: Importance Of Systematic Reviewsmentioning

confidence: 99%

Another Look at Outcomes and Outcome Measures in Psychiatry: Cui bono?

Arfken

Balon²

2013

Psychother Psychosom

View full text Add to dashboard Cite

“…Attempts to place aripiprazole into clinical perspective have included a Cochrane Collaboration review (El-Sayeh and Morganti 2004). All randomized clinical trials available at the time comparing aripiprazole with placebo and/or first- or second-generation antipsychotics for schizophrenia were analyzed.…”

Section: Is Aripiprazole Worth Using?mentioning

confidence: 99%

A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder

Citrome¹

2006

Neuropsychiatric Disease and Treatment

View full text Add to dashboard Cite

Aripiprazole has been approved by regulatory agencies for the treatment of schizophrenia and bipolar I disorder. Although it is a dopamine partial agonist, it also has substantial binding affinity for the serotonin 5HT2A receptor. Several double-blind randomized clinical trials have established the efficacy and tolerability of aripiprazole within the dose range of 10-30 mg/day for schizophrenia, and 15-30 mg/day for manic or mixed states associated with bipolar I disorder. Relatively few comparative trials with other secondgeneration antipsychotics have been published for schizophrenia, with none available for bipolar disorder. The evidence so far suggests that in terms of efficacy for schizophrenia, aripiprazole is superior to placebo and haloperidol (long term), similar to perphenazine and risperidone, and inferior to olanzapine. Its tolerability profile in patients with schizophrenia appears superior to haloperidol, perphenazine, risperidone, and olanzapine. Efficacy in treating manic or mixed states was established in placebo-controlled trials. Among some patients with bipolar disorder, akathisia and gastrointestinal (GI) complaints can emerge at the start of treatment; however, the GI symptoms were time-limited in many instances. Appropriate dosing may also be important in individualizing therapy to improve tolerability, with lower starting doses becoming more important when adding to, or switching from, another antipsychotic. Aripiprazole appears to have a low propensity for weight gain, a favorable metabolic profile, and no association with hyperprolactinemia.

show abstract

“…These results strongly suggest that blinding is important to avoid expectation biases in studies involving clinical endpoints. Aripiprazole, while clearly an efficacious treatment for schizophrenia (El-Sayeh and Morganti 2006), has been shown in a meta-analysis to be less efficacious than olanzapine (Leucht, Komossa et al 2009). Close clinical monitoring is necessary during and after a switch to aripiprazole or any other antipsychotic medication.…”

Section: Discussionmentioning

confidence: 99%

Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: Results from a randomized controlled trial

Stroup

Byerly

Nasrallah

et al. 2013

Schizophrenia Research

View full text Add to dashboard Cite

Purpose This study examined the clinical significance of switching from olanzapine, quetiapine, or risperidone to aripiprazole by examining changes in predicted risk of cardiovascular disease (CVD) according to the Framingham Risk Score (FRS) and metabolic syndrome status. FRS estimates 10-year risk of “hard” coronary heart disease (CHD) outcomes (myocardial infarction and coronary death) while metabolic syndrome is associated with increased risk of CVD, stroke, and diabetes mellitus. Method Changes in FRS and metabolic syndrome status were compared between patients with BMI ≥ 27 and non-HDL-C ≥ 130 mg/dL randomly assigned to stay on stable current treatment (olanzapine, quetiapine, or risperidone) or switch to treatment with aripiprazole with 24 weeks of follow-up. All study participants were enrolled in a behavioral program that promoted healthy diet and exercise. Results The pre-specified analyses included 89 switchers and 98 stayers who had post-baseline measurements needed to assess changes. Least squares mean estimates of 10-year CHD risk decreased more for the switch (from 7.0% to 5.2%) than the stay group (from 7.4% to 6.4%) (p=0.0429). The odds ratio for having metabolic syndrome (stay vs. switch) at the last observation was 1.748 (95% CI 0.919, 3.324, p=0.0885). Conclusion Switching from olanzapine, quetiapine, or risperidone to aripiprazole was associated with larger reductions in predicted 10-year risk of CHD than the behavioral program alone. The advantage of switching on metabolic syndrome was not statistically significant. The benefits of switching must be balanced against its risks, which in this study included more discontinuations of the study treatment but no significant increase in symptoms or hospitalizations.

show abstract

Aripiprazole for schizophrenia

Cited by 33 publications

References 0 publications

Another Look at Outcomes and Outcome Measures in Psychiatry: Cui bono?

Another Look at Outcomes and Outcome Measures in Psychiatry: Cui bono?

A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder

Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: Results from a randomized controlled trial

Contact Info

Product

Resources

About